Blogs About

During the recent Digital Pharma Innovation Week, I had the great opportunity to lead a roundtable discussion with a group of stakeholders from across the pharma industry...

As pharmaceutical companies evolve toward digital-first commercial models, U.S. market access strategies seem to be lagging in the digital revolution. Companies face many...

Non-adherence to prescribed therapy can create extraordinary risks for patients. Even when provided with correct diagnoses and effective treatment plans, patients can often...

There may be no greater threat to patient outcomes than the current barriers to therapy access—especially for specialty medications.

Growth in healthcare technology began with the HITECH (Health Information Technology for Economic and Clinical Health) Act of 2009 and has grown significantly over the years....

Every day, patients need to switch to new therapies because of disease progression, side effects, affordability or other factors—and if your brand is a second- or third-, or...

Over the past decade, pharma has made significant investments in real-world data (RWD) and in analytics/insights generated from that data -- real-world evidence (RWE). At ...

It’s a problem with enormous impact for patients that has been nearly impossible to solve: Brand-eligible patients are out there, but they’ve been misdiagnosed or, even...

Offering a Practical Approach to AI and Real-World Data

Despite incredible advances in the availability of real-world data (RWD) and AI applications, many tech-savvy brand...